Safety, Tolerability and Immunogenicity of a Maternal Respiratory Syncytial Virus (RSV) Vaccine (MKK900) in Healthy Adult Women

NCT07492706 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Respiratory Syncytial Virus (RSV)

Interventions

BIOLOGICAL: MKK900 60 µg
BIOLOGICAL: MKK900 120 µg
BIOLOGICAL: ABRYSVO®

Sponsor

MAXVAX Biotechnology Limited Liability Company